Limitations of Tc99m-MIBI-SPECT Imaging Scans in Persistent Primary Hyperparathyroidism by Witteveen, Janneke E. et al.
Limitations of Tc99m-MIBI-SPECT Imaging Scans in Persistent
Primary Hyperparathyroidism
Janneke E. Witteveen • Job Kievit •
Marcel P. M. Stokkel • Hans Morreau •
Johannes A. Romijn • Neveen A. T. Hamdy
Published online: 19 October 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Background In primary hyperparathyroidism (PHPT) the
predictive value of technetium 99m sestamibi single
emission computed tomography (Tc99m-MIBI-SPECT)
for localizing pathological parathyroid glands before a ﬁrst
parathyroidectomy (PTx) is 83–100%. Data are scarce in
patients undergoing reoperative parathyroidectomy for
persistent hyperparathyroidism. The aim of the present
study was to determine the value of Tc99m-MIBI-SPECT
in localizing residual hyperactive parathyroid tissue in
patients with persistent primary hyperparathyroidism
(PHPT) after initial excision of one or more pathological
glands.
Method We retrospectively evaluated the localizing
accuracy of Tc99m-MIBI-SPECT scans in 19 consecutive
patients with persistent PHPT who had a scan before
reoperative parathyroidectomy. We used as controls 23
patients with sporadic PHPT who had a scan before initial
surgery.
Results In patients with persistent PHPT, Tc99m-MIBI-
SPECT accurately localized a pathological parathyroid
gland in 33% of cases before reoperative parathyroidec-
tomy, compared to 61% before ﬁrst PTx for sporadic
PHPT. The Tc99m-MIBI-SPECT scan accurately localized
intra-thyroidal glands in 2 of 7 cases and a mediastinal
gland in 1 of 3 cases either before initial or reoperative
parathyroidectomy.
Conclusions Our data suggest that the accuracy of
Tc99m-MIBI-SPECT in localizing residual hyperactive
glands is signiﬁcantly lower before reoperative parathy-
roidectomy for persistent PHPT than before initial surgery
for sporadic PHPT. These ﬁndings should be taken in
consideration in the preoperative workup of patients with
persistent primary hyperparathyroidism.
Introduction
Primary hyperparathyroidism is one of the most common
endocrine disorders. Surgical removal of all pathological
parathyroid tissue is the only therapy that leads to deﬁnitive
and durable cure. The need for preoperative localization of
pathological parathyroid gland(s) before initial surgery
depends on the chosen surgical approach. In case of tra-
ditional bilateral neck exploration, localization studies are
not deemed necessary because experienced surgeons have,
on average, a 98% chance of excising all pathological
tissue, as the procedure entails visualization of all four
parathyroid glands [1, 2]. However, localization studies
become mandatory when the surgeon opts for a more
focused unilateral or minimally invasive approach. Accu-
rate localization studies are even more important before
reoperative parathyroidectomy for persistent hyperpara-
thyroidism, as a second (or more) neck exploration is
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be associated with as much as a threefold increase in
morbidity [1, 3–5]. Persistent hyperparathyroidism is
reported to occur in 2–7% of patients who have had a
parathyroidectomy [1, 6, 7]. Excluding insufﬁcient expe-
rience of the operating surgeon, persistent PHPT may be
caused by a second adenoma, multiple gland hyperplasia,
an ectopically located hyperactive gland undetected at
initial surgery, or, rarely, parathyromatosis from gland
spillage during initial surgery [8].
Technetium 99m sestamibi (Tc99m-MIBI), particularly
when complemented by single emission computed
tomography (Tc99m-MIBI-SPECT), is a widely used
imaging technique for the preoperative localization of
parathyroid adenomas [1, 9]. Tc99m-MIBI-SPECT has a
sensitivity ranging from 66 to 90% and a positive predic-
tive value ranging from 83 to 100% for pathological
parathyroid glands [1, 10–17]. However, the test is also
known to have lower sensitivity for small adenomas
weighing\500 mg [15, 18] and in the presence of multiple
gland pathology [1, 9, 15, 17–20].
Tc99m-MIBI was originally developed for myocardial
perfusion imaging. It is a monovalent lipophilic cation that
diffuses passively through cell membranes and accumu-
lates almost exclusively in mitochondria following nega-
tive membrane potentials [21]. The imaging technique has
been used to detect benign tumors as well as several pri-
mary malignancies and metastatic tumors [22]. In primary
hyperparathyroidism, the mechanism by which Tc99m-
MIBI can localize a pathological parathyroid gland is based
on the increased uptake of the radiopharmaceutical by
functionally hyperactive glands; on the abundance of
mitochondria in parathyroid oxyphil cells, which sequester
sestamibi intracellularly; and on the increased perfusion of
hyperactive parathyroid glands. However, imaging studies
are often negative in persistent hyperparathyroidism.
Potential contributory factors to false negative scans are a
postoperative disturbance in the perfusion of remaining
pathological glands and a predominance of parathyroid
chief cells, which are poorer in mitochondrial content
compared to oxyphil cells [18].
In patients undergoing reoperative parathyroidectomy
for persistent hyperparathyroidism, the accuracy of Tc99m-
MIBI-SPECT in localizing hyperactive parathyroid tissue
has been largely assessed in mixed patient groups,
including patients in whom no parathyroid tissue was found
at initial surgery [23, 24], patients with a known MEN-1
(multiple endocrine neoplasia type 1) mutation [25], and
patients with secondary or tertiary hyperparathyroidism
[26, 27]. Data on the ability of Tc99m-MIBI-SPECT to
detect and localize residual hyperactive parathyroid tissue
in patients with persistent primary hyperparathyroidism are
particularly scarce. The available data do suggest, however,
that the predictive value of this technique falls dramatically
from 80% or higher before initial surgery for single gland
disease (SGD) to as low as 50% before reoperative para-
thyroidectomy for persistent PHPT [28–30]. Because
reoperative parathyroidectomy may be associated with
increased morbidity, accurate localization of residual
hyperactive tissue becomes of paramount importance in
patients with persistent PHPT [28–30]. Correct preopera-
tive localization of a hyperactive parathyroid gland by
Tc99m-MIBI-SPECT would allow for more focused and
efﬁcient exploration, thus reducing the risk of damage to
the recurrent laryngeal nerve(s) and signiﬁcantly increasing
the likelihood of cure.
The aim of the present study was to determine the ability
of Tc99m-MIBI-SPECT to detect and localize residual
hyperactive parathyroid glands prior to reoperative para-
thyroidectomy in patients with persistent PHPT.
Patients
Using hospital records, we identiﬁed 19 consecutive
patients who required reoperative parathyroidectomy for
persistent hyperparathyroidism and who had had parathy-
roid localization studies with Tc99m-MIBI-SPECT before
surgery. These were 14 women and 5 men with a mean age
of 55 ± 12 years at diagnosis, who had undergone between
one and three unsuccessful earlier neck explorations.
Sixteen of the 19 patients had their initial surgery and
earlier reoperations, if applicable, at other institutions and
were referred to our unit for further workup before reop-
erative parathyroidectomy. We compared these patients
with 23 patients with sporadic primary hyperparathyroid-
ism due to single gland disease who also had had a Tc99m-
MIBI-SPECT scan prior to initial surgery. These were,
respectively, 21 women and 2 men with a mean age of
59 ± 12 years at diagnosis. All surgical procedures were
undertaken by two surgeons with considerable experience
in endocrine surgery.
Methods
Demographic data, operative data, preoperative and post-
operative laboratory data, and histological ﬁndings were
obtained from patients’ hospital records. In the present
study, cure is deﬁned as sustained normal serum calcium
and PTH concentrations more than 6 months after para-
thyroidectomy [6]. Persistent hyperparathyroidism is
deﬁned as persistently elevated serum calcium and PTH
concentrations in consecutive samples within and beyond
6 months after surgery [6].
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by an experienced pathologist. A diagnosis of parathyroid
adenoma was based on the presence of a benign encapsu-
lated neoplasm usually involving a single gland with an
adjacent rim of normal glandular tissue [31]. Parathyroid
hyperplasia was deﬁned as an absolute increase in para-
thyroid parenchymal cell mass resulting from proliferation
of chief cells, oncocytic cells, and transitional oncocytic
cells in multiple parathyroid glands in the absence of a
known stimulus for PTH hypersecretion such as renal
failure or vitamin D deﬁciency [31]. A diagnosis of
hyperplasia was also favored when synchronous multi-
glandular disease was found at operation.
Tc99m-MIBI-SPECT imaging technique
The Tc99m-MIBI-SPECT scan was performed as follows:
after intravenous injection of 500 MBq of Tc99m meth-
oxy-isobutyl-isonitrile (MIBI), planar images of the head
and neck region and chest were performed at a matrix size
of 256 9 256 (10 min per frame). Scintigraphy was per-
formed as a dual-phase single tracer examination. Images
were acquired with the patient in the supine position,
15 min and 2 h after injection of the radiopharmaceutical.
A gamma camera (Toshiba GCA-7200, Tokyo, Japan)
equipped with low-energy high-resolution (LEHR) colli-
mators was used for image acquisition. Single photon
emission computed tomography (SPECT) was performed
in a 128 9 128 matrix size, using a step angle of 4 and a
step time of 35 s per step, 90 min after the injection. The
ﬁltered back projection was used for image reconstruction,
using a Butterworth ﬁlter (8 order, subset 12). All Tc99m-
MIBI-SPECT scans were reviewed by an experienced
nuclear medicine physician who was blinded to the out-
come of the surgical procedure.
Surgical procedures
Bilateral neck exploration consisted of visualization of all
four parathyroid glands, followed by either excision of a
single enlarged parathyroid gland or subtotal or total
parathyroidectomy with auto transplantation if more than
one parathyroid gland was found to be enlarged. If not all
four parathyroid glands could be visualized and no
enlarged parathyroid gland was found, dissection of the
ipsilateral anterior compartment extending from the level
of the hyoid bone superiorly to the suprasternal notch
inferiorly and hemithyroidectomy were undertaken on the
side of the missing parathyroid. Unilateral neck exploration
and minimally invasive neck exploration were guided by
intraoperative PTH measurement.
Analysis of data
The ability of Tc99m-MIBI-SPECT to detect and localize
hyperactive parathyroid tissue was evaluated in three dif-
ferent ways, thereby providing the answers to three dif-
ferent questions that are clinically relevant to the operating
surgeon.
The ﬁrst question we addressed is ‘‘Is the Tc99m-MIBI-
SPECT scan able to detect any parathyroid hyperactivity?’’
This question relates to the overall sensitivity of the scan
for detecting the presence of hyperactive parathyroid tissue
in the scanned neck and mediastinal regions (Fig. 1). A
scan was considered true positive when it correctly iden-
tiﬁed the presence of an abnormal gland at any site. A scan
was considered true negative when no pathological para-
thyroid gland(s) was found at surgery and no presence of
hyperactive parathyroid tissue was suggested by the scan.
A scan was considered false positive when no pathological
glands were found at operation, although the scan had
suggested the presence of hyperactive parathyroid tissue.
Fig. 1 Positive Tc99m-MIBI-
SPECT imaging scan
demonstrating increased
radioactive pharmaceutical
uptake in the right lower neck
suggesting a pathological
parathyroid gland in this
location (a), concurring with
subsequent operative ﬁndings of
a 2.5 cm pathological
parathyroid adenoma (b)
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123A scan was considered false negative when a pathological
parathyroid gland was removed at surgery, although the
scan had not demonstrated the presence of hyperactive
parathyroid tissue.
The second question addressed is ‘‘Is the scan able to
lateralize the area of hyperactive parathyroid tissue, thus
indicating which side of the neck should be explored?’’ This
questionrelatestothesensitivityandspeciﬁcityofthescanin
identifying the side of the neck in which hyperactive para-
thyroid tissue is localized (Fig. 2a). A true positive side was
deﬁnedasanecksidefromwhichapathologicalparathyroid
gland was removed at surgery, and in which the presence of
hyperactive parathyroid tissue was suggested by the preop-
erativelocalizationtest.Atruenegativesidewasdeﬁnedasa
neck side in which no pathological parathyroid gland was
found at surgery, and in which no presence of hyperactive
parathyroid tissue was suggested by the preoperative local-
izationtest.Afalsepositivesidewasdeﬁnedasanecksidein
which no pathological parathyroid gland was found at sur-
gery,althoughthepresenceofhyperactiveparathyroidtissue
was suggested by the preoperative localization test. A false
negative side was deﬁned as a neck side from which a
pathological parathyroid gland was removed at surgery,
although no presence of hyperactive parathyroid tissue was
suggested by the preoperative localization test.
The third question is ‘‘Is the scan able to accurately
localize the region of the neck where the hyperactive para-
thyroid tissue is present?’’, thus providing an even smaller
operative ﬁeld for the surgeon to focus on. This third
question takes accuracy of localization of the imaging
modality a step further by identifying the localization of the
hyperactive parathyroid tissue in any of 5 designated ana-
tomical areas of the neck (four thyroid quadrants, and a ﬁfth
‘‘elsewhere’’ area combining all possible ectopic localiza-
tions in the mediastinum) (Fig. 2b). With respect to the risk
of damaging the recurrent laryngeal nerve, a correct answer
to question 2 would limit the risk to one nerve only, whereas
a correct answer to question 3 would provide additional
information on the magnitude of this risk by identifying the
speciﬁc region to be explored. A true positive region was
deﬁned as a region from which a pathological parathyroid
gland was removed at surgery, and in which the presence of
hyperactive parathyroid tissue was suggested by the pre-
operative localization test. A true negative region was
deﬁned as a region in which no pathological parathyroid
gland was found at surgery, and in which no presence of
hyperactive parathyroid tissue was suggested by the pre-
operative localization test. A false positive region was
deﬁned as a region in which no pathological parathyroid
gland was found at surgery, although the presence of
hyperactive parathyroid tissue was suggested in this region
by the preoperative localization test. A false negative region
was deﬁned as a region from which a pathological para-
thyroid gland was removed at surgery, although no presence
of hyperactive parathyroid tissue was suggested in this
region by the preoperative localization test.
True negative and false positive scans, sides or regions
could only be determined in patients who were cured after
the surgery by the ﬁnding and removal of a pathological
parathyroid gland elsewhere in the neck or mediastinum
Fig. 2 Analysis of the ability of
Tc99m-MIBI-SPECT scan to
correctly localize a pathological
parathyroid gland as conﬁrmed
by localization at surgery by
dividing the neck into two
anatomical areas (the right and
left side of the neck) (a) or into
ﬁve anatomical areas (the four
thyroid quadrants and a ﬁfth
area of all possible ectopic
localizations in the
mediastinum) (b)
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and speciﬁcity by false negative surgery).
In all three analyses widely accepted deﬁnitions for
sensitivity and speciﬁcity were used to address each of the
three different questions posed. Sensitivity was thus judged
to be the power of the test to identify the presence of path-
ological parathyroid glands at any site regardless of accu-
racy of localization (question 1), on the correct side of the
neck(question2),orintheexactregionofneck(question3).
Speciﬁcity was judged to be the power of Tc99m-MIBI-
SPECT to recognize the absence of a pathological para-
thyroid gland in the truly negative side of the neck (question
2) or in the exact region of the neck (question 3).
Statistical analysis
Statistical analysis was performed with SPSS 16 software
(SPSS, Inc., Chicago, IL). Results are expressed as
mean ± SD unless otherwise stated. Baseline characteris-
tics of the patient groups were compared with one-way
analysis of variance (ANOVA) for continuous variables,
and the chi-square statistic was used for comparison of
categorical variables. A probability level of random
difference of P\0.05 was considered signiﬁcant.
Results
Demographic data
Patients who underwent reoperative parathyroidectomy for
persistent PHPT did not differ signiﬁcantly in age and
gender from patients who underwent initial surgery for
sporadic PHPT. Also, laboratory data before operation did
not differ signiﬁcantly between the two patient groups
(Table 1).
Operative data and postoperative cure
Bilateral neck exploration was more frequently performed
in patients with persistent hyperparathyroidism undergoing
reoperative parathyroidectomy (84%) than in patients with
a single adenoma undergoing initial surgery (56%)
(Table 1).
At least one and up to three hyperactive parathyroid
glands had been removed at initial surgery in patients with
persistent hyperparathyroidism. The 18 pathological para-
thyroid glands removed at reoperative parathyroidectomy
were removed from ectopic locations (n = 8; 44%):
intrathyroidal (n = 4), thymus (n = 2), mediastinum (n =
1), and a location ventral to the trachea (n = 1). Other
glands were removed from expected anatomical locations
in the right lower quadrant (n = 4), right upper quadrant
(n = 3), left lower quadrant (n = 2), and left upper
quadrant (n = 1) of the neck.
Complete cure was eventually achieved in 11 of the 19
patients (58%). Of the remaining 8 patients, 6 had no
further surgery, 1 had one further operation, and 1 had
three further operations, which resulted in improvement in
the severity of the hyperparathyroidism but not in complete
Table 1 Demographic,
laboratory, operative, and
pathology data of patients who
had a Tc99m-MIBI-SPECT
scan prior to initial surgery
for sporadic primary
hyperparathyroidism (PHPT)
or prior to reoperative
parathyroidectomy for
persistent PHPT
s serum
a Reference range
2.15–2.55 mmol/l
b Reference range 1.5–8 pmol/l
Persistent PHPT Sporadic PHPT P value
(n = 19) (n = 23)
Age, years (±SD) 55 ± 12 59 ± 12 0.274
Sex, M:F 5:14 2:21 0.127
Preoperative laboratory data
s-Corrected calcium, mmol/l 2.88 ± 0.35 2.80 ± 0.23 0.399
s-PTH, pmol/l 16.2 ± 9.3 24.5 ± 20.2 0.131
Postoperative laboratory data
s-Corrected calcium, mmol/l
a 2.46 ± 0.28 2.29 ± 0.13 0.027
s-PTH, pmol/l
b 10.0 ± 11.7 4.0 ± 2.7 0.043
Operative data
Bilateral exploration 16 (84%) 13 (56%) 0.053
Unilateral exploration 3 (16%) 5 (22%) 0.625
Minimally invasive 0 5 (22%) 0.030
Pathology data
Adenoma 8 (42%) 19 (83%) 0.037
Hyperplasia 9 (47%) 4 (17%) 0.152
No pathological glands 2 (11%) 0 0.210
Gland diameter, cm (± SD) 1.21 ± 0.93 2.03 ± 1.40 0.062
Fig. 3 Flowchart of the answers to the three clinical questions
addressed in 19 patients who had preoperative parathyroid localiza-
tion studies with Tc99m-MIBI-SPECT prior to reoperative parathy-
roidectomy for persistent PHPT
c
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123cure as deﬁned in our study. In all 8 patients the decision to
withhold further surgery was based on a combination of
lack of severe symptoms, mild biochemical features of
hyperparathyroidism, and the increased morbidity risk
associated with further surgery in the context of prior
extensive neck exploration, which had to be extended to
mediastinal exploration in some cases.
The 23 patients with PHPT who had a Tc99m-MIBI-
SPECT scan prior to initial surgery for sporadic PHPT
were all cured, and cure was sustained for a mean duration
of 47 months (range: 6–188 months) after PTx. Patholog-
ical parathyroid glands removed at surgery were predom-
inantly located in the right (n = 10, 43%) or left (n = 7,
30%) lower thyroid quadrants, and only 1 pathological
gland was located in the right upper quadrant of the neck.
Five successfully removed ectopic glands had been in
subcapsular thyroidal (n = 2), intrathyroidal (n = 1), or
mediastinal (n = 2) locations.
Histological data
On histological examination, 42% of the patients with
persistent hyperparathyroidism had a second adenoma and
47% had hyperplastic parathyroid gland(s) (Table 1). A
single adenoma was removed in 83% of the patients who
underwent initial surgery for sporadic PHPT. The average
diameter of a pathological parathyroid gland found at
reoperative parathyroidectomy for persistent PHPT was
smaller (1.21 cm) compared to the average size of glands
found at initial surgery for sporadic PHPT (2.03 cm).
Value of Tc99m-MIBI-SPECT scans prior
to reoperative parathyroidectomy for persistent PHPT
In total, 18 hyperactive parathyroid glands were removed at
reoperative parathyroidectomy from 19 patients with per-
sistent PHPT. One hyperactive parathyroid gland was
removed in 16 of these patients, 2 glands in 1 patient, and
no pathological glands could be found in the other 2
patients despite extensive bilateral neck and mediastinal
explorations. Tc99m-MIBI-SPECT demonstrated increased
radiotracer uptake, suggesting parathyroid hyperactivity in
only 9 of the 19 patients (47%) (Fig. 3).
At reoperative parathyroidectomy 15 patients had a
pathological gland removed from the neck region. Tc99m-
MIBI-SPECT was able to identify the correct side of the
neck in 5 of these 15 patients (33%) (Table 2; Fig. 3).
Tc99m-MIBI-SPECT was able to detect and accurately
localize only 6 of the 18 pathological glands removed at
reoperative parathyroidectomy either from the neck or
from ectopic locations (33%) (Table 3; Fig. 3). Two of
these glands, an adenoma and a hyperplastic gland, were
found in normal anatomical locations in the left upper and
left lower thyroid quadrants, and 4 glands were found in
ectopic locations in the neck, one adenoma was in the
thymus, one adenoma and one hyperplastic gland were in
the thyroid, and one adenoma was located ventral to the
trachea, caudally in the neck.
Of the 12 pathological glands not accurately localized
by Tc99m-MIBI-SPECT, 67% were hyperplastic glands
and 33% were adenomas. Only 4 of the 12 glands missed at
Tc99m-MIBI-SPECT were found in an ectopic location at
surgery: one hyperplastic gland was in the thymus, one
adenoma and one hyperplastic gland were in the thyroid
gland, and one hyperplastic gland was in the mediastinum.
Pathological glands with negative imaging were smaller,
with a mean diameter of 9 mm, ranging from 5 to 16 mm,
and had a histological predominance of chief cells.
Value of Tc99m-MIBI-SPECT scans prior to initial
surgery for sporadic PHPT
All 23 patients with sporadic PHPT had one hyperactive
parathyroid gland removed at initial surgery and achieved
Table 2 Predictive value of Tc99m-MIBI-SPECT for the localization of pathological parathyroid glands in the correct side of the neck
% Sensitivity % Speciﬁcity % PPV % NPV
Before initial surgery for sporadic PHPT (n = 23) 67 100 100 75
Before reoperative parathyroidectomy for persistent PHPT (n = 19) 33 80 63 53
PPV positive predictive value, NPV negative predictive value
Table 3 Predictive value of Tc99m-MIBI-SPECT for the localization of pathological parathyroid glands in the exact region of the neck
% Sensitivity %Speciﬁcity % PPV % NPV
Before initial surgery for sporadic PHPT (n = 23) 61 99 93 91
Before reoperative parathyroidectomy for persistent PHPT (n = 19) 33 95 67 84
Fig. 4 Flowchart of the answers to the three clinical questions
addressed in 23 patients who had preoperative parathyroid localiza-
tion studies with Tc99m-MIBI-SPECT prior to initial surgery for
sporadic PHPT
c
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123cure. However, Tc99m-MIBI-SPECT scan demonstrated
increased radiotracer uptake, suggesting parathyroid
hyperactivity in only 15 of the 23 patients (65%) (Fig. 4).
In 21 of the 23 patients the hyperactive parathyroid gland
was removed from the neck. Tc99m-MIBI-SPECT was
able to identify the correct side of the neck in 14 of these
patients (67%) (Table 2; Fig. 4). In 2 of the 23 patients a
hyperactive gland was removed from the mediastinum, but
Tc99m-MIBI-SPECT was able to detect only one of these
glands (Fig. 4).
Tc99m-MIBI-SPECT was able to accurately localize 14
of the 23 pathological parathyroid glands removed at
operation (61%) (Table 3; Fig. 4). Of the 14 glands accu-
rately localized by Tc99m-MIBI-SPECT, 12 (86%) were
adenomas located in the right lower thyroid quadrant in 9
cases (76%), in the left lower thyroid quadrant in 2 cases
(17%), and in the mediastinum in 1 case (7%). The
remaining 2 accurately localized glands were hyperplastic
parathyroid glands located in the left lower thyroid quad-
rant. Of the 9 pathological glands that were not localized or
that were inaccurately localized by Tc99m-MIBI-SPECT,
5 were found in the neck in expected anatomical locations
at surgery and 4 were ectopically located: 3 intrathyroidally
and 1 in the mediastinum. Intrathyroidal parathyroid glands
were found in 2 cases by visualization during extensive
bilateral neck exploration and in 1 case during unilateral
neck exploration combined with intraoperative PTH
(IOPTH) measurement. The mediastinal gland was found
during thoracic extension of a full bilateral neck explora-
tion during which no pathological parathyroid glands were
found in the neck.
Limitations of Tc99m-MIBI-SPECT imaging studies
Localization ability for pathological parathyroid glands
in anatomically expected versus ectopic locations
Combining all patients included in this study, pathological
parathyroid glands were most frequently found in the right
(37%) and left (32%) lower thyroid quadrants (Fig. 5).
Thirteen of the 41 pathological glands removed at surgery
(32%) were found in ectopic locations: intrathyroidally
(n = 7), in the thymus (n = 2), in the mediastinum
(n = 3), and ventral to the trachea in the neck (n = 1). An
intrathyroidal parathyroid gland was accurately localized
preoperatively in 2 of 7 cases (29%), a mediastinal gland in
1 of 3 cases (33%), a gland in the thymus in 1 of 2 cases
(50%), and a gland ventral to the trachea in one case
(100%).
Tc99m-MIBI-SPECT scan had a lower sensitivity for
pathological parathyroid glands identiﬁed at surgery in the
upper quadrants of the neck (2/9 = 22%), than for glands
found in the lower quadrants of the neck (16/28 = 57%)
(Fig. 5). None of the 7 pathological parathyroid glands in
the right upper thyroid quadrant could be accurately
localized preoperatively. One of the 7 pathological glands
in the right upper thyroid quadrant showed uptake in the
right lower quadrant, and the other 6 glands showed no
radiotracer uptake on Tc99m-MIBI-SPECT.
Localization ability for adenomas versus hyperplastic
pathological glands
In the present study, Tc99m-MIBI-SPECT scan was able to
accurately localize 16 of 26 adenomas (64%) and 4 of 16
hyperplastic glands (25%) found at surgery.
Localization ability in relation to pathological parathyroid
gland size
Pathological parathyroid glands with a diameter greater
than 1.5 cm were more frequently accurately localized by
Tc99m-MIBI-SPECT than glands with a diameter smaller
than 1.5 cm. In patients undergoing initial surgery for
sporadic PHPT, Tc99m-MIBI-SPECT had a sensitivity of
71% for glands with a diameter [1.5 cm compared to a
Fig. 5 Combined number of pathological parathyroid glands identi-
ﬁed at initial surgery (n = 23) and at revision surgery (n = 18) in
each of the four quadrants of the neck and the mediastinum. The
sensitivity of Tc99m-MIBI-SPECT for localization in each of these
four quadrants of the neck and the mediastinum is shown in
parentheses
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patients who underwent reoperative parathyroidectomy for
persistent PHPT, Tc99m-MIBI-SPECT had a sensitivity of
50% for glands with a diameter[1.5 cm and a sensitivity
of 14% for glands with a diameter\1.5 cm.
Localization ability in relation to parathyroid pathology
In patients undergoing initial surgery, 81% of pathological
glands, whether adenomatous or hyperplastic, had a pre-
dominance of chief cells and only 19% had a predominance
of oxyphil cells. In patients undergoing reoperative para-
thyroidectomy for persistent PHPT, 59% of pathological
glands had a predominance of chief cells, 12% had a pre-
dominance of oxyphil cells and the remaining glands had a
combination of cell types. In patients who underwent initial
surgery for sporadic PHPT, Tc99m-MIBI-SPECT was
more sensitive in localizing pathological parathyroid
glands with a predominance of oxyphil cells compared to
those with a predominance of chief cells (100 vs. 47%,
respectively). This higher sensitivity for pathological
parathyroid glands with a predominance of oxyphil cells
could not be replicated in patients who underwent reoper-
ative parathyroidectomy for persistent PHPT.
Discussion
Our ﬁndings from the present study underline the limita-
tions of the Tc99m-MIBI-SPECT imaging technique in the
accurate preoperative localization of residual pathological
parathyroid glands before reoperative parathyroidectomy in
patients with persistent hyperparathyroidism. Advances in
imaging technology have promoted the development of
more focused approaches in the surgical management of
primary hyperparathyroidism. The preoperative localiza-
tion of a pathological parathyroid gland is, however, a
prerequisite for a unilateral or minimally invasive surgical
approach. Although more than 80% of patients with spo-
radic primary hyperparathyroidism will have a single
adenoma, it has been estimated that 15–20% will have a
double adenoma or four-gland hyperplasia [32, 33]. Ten
percent of individuals may also have supernumerary glands
(5–7 glands) [34–36], so that it is not surprising that some
of these pathological glands may be missed at initial sur-
gery. It has indeed been reported that 1–7% of patients with
primary hyperparathyroidism will have persistent hyper-
parathyroidism after initial surgery [6, 37, 38]. When this is
the case, it becomes essential to accurately localize the
residual hyperactive glands if morbidity from reoperative
parathyroidectomy is to be signiﬁcantly decreased [39].
Limited data suggest that the localizing value of Tc99m-
MIBI-SPECT is much lower for the preoperative
localization of residual active parathyroid glands before
reoperative parathyroidectomy [28–30]. Findings from the
present study conﬁrm this notion and emphasize that the
ability of Tc99m-MIBI-SPECT to detect and to accurately
localize residual hyperactive glands is signiﬁcantly jeop-
ardized in patients with persistent hyperparathyroidism
before reoperative parathyroidectomy compared to its
detection and localization ability for pathological para-
thyroid glands before initial surgery for sporadic PHPT.
Several factors may play a role in this decrease in the
scan’s ability to detect and accurately localize hyperactive
parathyroid glands in persistent PHPT. Compared to
patients with sporadic PHPT cured after initial surgery,
patients with persistent hyperparathyroidism had a lower
proportion of adenomas (44 vs. 74%), a higher proportion
of hyperplastic glands (55 vs. 26%), more ectopically
located glands (44 vs. 22%), and smaller pathological
gland size (1.21 vs. 2.03 cm). Published data do indeed
suggest a lower predictive value for Tc99m-MIBI-SPECT
in cases of parathyroid hyperplasia, ectopic glands, and
glands of small size [10, 15, 18, 19, 40, 41]. Patients with
persistent HPTH are also at a higher risk from parathyro-
matosis due to potential spillage during sometimes multiple
earlier surgical procedures.
With Tc99m-MIBI imaging, the radiopharmaceutical
uptake of pathological parathyroid glands depends not only
on perfusion of the hyperactive gland but also on mito-
chondrial activity of the hyperactive cells. In the parathy-
roid gland, oxyphil cells have an abundance of
mitochondria compared to chief cells. Studies focusing on
the causes for negative Tc99m-MIBI-SPECT imaging
suggest an inﬂuence of the presence of mitochondria-rich
cells on outcome. Mihai et al. [18] and Erbil et al. [42]
found that Tc99m-MIBI-SPECT scans were more fre-
quently positive than negative in the case of adenomas rich
in mitochondria-abundant oxyphil cells. In contrast,
Westerdahl and Bergenfelz [19] found no difference in the
positive or negative imaging of predominantly oxyphil-rich
adenomas.
Parathyroid adenomas are mainly composed of chief
cells, and it could be argued that sestamibi may not be
taken up by these pathological glands. This is not the
case, however, as demonstrated by the frequent ﬁnding of
both chief cells and oxyphil cells—although in different
percentages—in parathyroid adenomas. When both types
of cells are found, the net number of mitochondria-rich
cells would depend in large part on the size of the
pathological gland. The same applies for hyperplastic
glands. In keeping with published data, we also observe a
clear relationship between gland size and localizing
accuracy of Tc99m-MIBI-SPECT. The accuracy of a
Tc99m-MIBI-SPECT scan is thus determined mainly by
size and amount of oxyphil cells rather than by the
World J Surg (2011) 35:128–139 137
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hyperplastic nature of the gland.
Our ﬁndings from the present study demonstrate that the
ability of the widely used Tc99m-MIBI-SPECT to detect
and accurately localize pathological parathyroid glands is
signiﬁcantly limited in patients with persistent hyperpara-
thyroidism before reoperative parathyroidectomy.
Although the precise cause for this remains unclear, it is
likely to be multifactorial, and probably includes distur-
bances in the local vascular supply caused by previous
surgery, as well as differences in gland pathology and size
ultimately affecting radiopharmaceutical uptake. It is also
conceivable that a previous scan may also have been
unable to localize hyperactive parathyroid gland(s) in a
speciﬁc individual prior to initial surgery. Because most
patients in this series did not have preoperative scans
before their initial surgery, however, addressing the ques-
tion of the general ability of Tc99m-MIBI-SPECT to
localize a hyperactive parathyroid gland in a speciﬁc
individual is impossible and represents a limitation of the
present study.
Our data hold signiﬁcant implications in the manage-
ment of patients with persistent hyperparathyroidism. From
the practical point of view, and in keeping with recent
guidelines of the European Association of Nuclear Medi-
cine [43], our data suggest that it is always worth per-
forming a Tc99m-MIBI-SPECT scan as a ﬁrst preoperative
localization study in patients with either sporadic or per-
sistent hyperparathyroidism. Should the scan fail to dem-
onstrate increased uptake in neck or mediastinum, no effort
should be spared to attempt further localization of residual
hyperactive glands prior to surgery to minimize morbidity.
For instance, it is possible to use the invasive but more
reliable PTH venous sampling technique (our own
unpublished observations), followed by a high-resolution
4-dimensional CT scan of the area of interest. Should the
scan be able to lateralize the lesion to the right or left side
of the neck, it would be reasonable to undertake more
limited unilateral neck exploration under the umbrella of
intraoperative PTH measurements. Whether the recently
advocated use of double-tracer subtraction parathyroid
scintigraphy [43] is able to provide better detection and
localization accuracy for residual hyperactive parathyroid
glands than Tc99m-MIBI-SPECT imaging in the difﬁcult
group of patients with persistent hyperparathyroidism
remains to be established.
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